Article

Key clinical point: Dupilumab was more effective than topical corticosteroids (TCS) and cyclosporine in reducing the severity of atopic dermatitis (AD) and transepidermal water loss (TEWL), both in eczematous lesions and nonlesioned skin.

Major finding: At week 16, a higher proportion of patients receiving dupilumab vs cyclosporine or TCS achieved 50% improvement in the Eczema Area and Severity Index (EASI-50; 81.8% vs 28.6% or 40.0% respectively; P  =  .004). TEWL reduced with both dupilumab (P < .001) and TCS (P  =  .047) in eczematous lesions and with dupilumab in nonlesioned skin (P  =  .006) with dupilumab treatment being associated with achievement of EASI-50 (odds ratio 10.67; P  =  .026) and 50% improvement in TEWL (P  =  .004).

Study details: Findings are from a prospective, observational study including 46 patients with AD who received TCS (n = 10), cyclosporine (n = 14), or dupilumab (n = 22).

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Montero-Vilchez T et al. Dupilumab improves skin barrier function in adults with atopic dermatitis: A prospective observational study. J Clin Med. 2022;11(12):3341 (Jun 10). Doi:  10.3390/jcm11123341

Key clinical point: Dupilumab was more effective than topical corticosteroids (TCS) and cyclosporine in reducing the severity of atopic dermatitis (AD) and transepidermal water loss (TEWL), both in eczematous lesions and nonlesioned skin.

Major finding: At week 16, a higher proportion of patients receiving dupilumab vs cyclosporine or TCS achieved 50% improvement in the Eczema Area and Severity Index (EASI-50; 81.8% vs 28.6% or 40.0% respectively; P  =  .004). TEWL reduced with both dupilumab (P < .001) and TCS (P  =  .047) in eczematous lesions and with dupilumab in nonlesioned skin (P  =  .006) with dupilumab treatment being associated with achievement of EASI-50 (odds ratio 10.67; P  =  .026) and 50% improvement in TEWL (P  =  .004).

Study details: Findings are from a prospective, observational study including 46 patients with AD who received TCS (n = 10), cyclosporine (n = 14), or dupilumab (n = 22).

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Montero-Vilchez T et al. Dupilumab improves skin barrier function in adults with atopic dermatitis: A prospective observational study. J Clin Med. 2022;11(12):3341 (Jun 10). Doi:  10.3390/jcm11123341

Key clinical point: Dupilumab was more effective than topical corticosteroids (TCS) and cyclosporine in reducing the severity of atopic dermatitis (AD) and transepidermal water loss (TEWL), both in eczematous lesions and nonlesioned skin.

Major finding: At week 16, a higher proportion of patients receiving dupilumab vs cyclosporine or TCS achieved 50% improvement in the Eczema Area and Severity Index (EASI-50; 81.8% vs 28.6% or 40.0% respectively; P  =  .004). TEWL reduced with both dupilumab (P < .001) and TCS (P  =  .047) in eczematous lesions and with dupilumab in nonlesioned skin (P  =  .006) with dupilumab treatment being associated with achievement of EASI-50 (odds ratio 10.67; P  =  .026) and 50% improvement in TEWL (P  =  .004).

Study details: Findings are from a prospective, observational study including 46 patients with AD who received TCS (n = 10), cyclosporine (n = 14), or dupilumab (n = 22).

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Montero-Vilchez T et al. Dupilumab improves skin barrier function in adults with atopic dermatitis: A prospective observational study. J Clin Med. 2022;11(12):3341 (Jun 10). Doi:  10.3390/jcm11123341

Key clinical point: Patients with moderate-to-severe atopic dermatitis (AD) who did not achieve Investigator's Global Assessment (IGA) 0/1 response with abrocitinib at week 12, still achieved clinically meaningful improvements in AD severity, itch, and quality of life.

Major finding: At week 12, a higher proportion of IGA nonresponders receiving 200 and 100 mg abrocitinib vs placebo achieved ≥ 75% improvement in the Eczema Area and Severity Index (41.0% and 27.0% vs 9.4%, respectively), ≥4-point improvement in itch (42.8% and 35.2% vs 18.2%, respectively), and ≥4-point improvement in Dermatology Life Quality Index (67.6% and 75.0% vs 49.5%, respectively) scores.

Study details: Findings are from a post hoc analysis of 1 phase 2b and 2 phase 3 (JADE Mono-1 and JADE Mono-2) trials including 548 patients with moderate-to-severe AD who were randomly assigned to receive abrocitinib (200 or 100 mg) or placebo and did not achieve IGA 0/1 response.

Disclosures: This study was funded by Pfizer Inc. Five authors declared being current or former employees and shareholders of Pfizer. The other authors reported ties with various sources, including Pfizer.

Source: Blauvelt A et al. Abrocitinib monotherapy in Investigator’s Global Assessment nonresponders: Improvement in signs and symptoms of atopic dermatitis and quality of life. J Dermatolog Treat. 2022 (Jul 6). Doi: 10.1080/09546634.2022.2059053

Key clinical point: Patients with moderate-to-severe atopic dermatitis (AD) who did not achieve Investigator's Global Assessment (IGA) 0/1 response with abrocitinib at week 12, still achieved clinically meaningful improvements in AD severity, itch, and quality of life.

Major finding: At week 12, a higher proportion of IGA nonresponders receiving 200 and 100 mg abrocitinib vs placebo achieved ≥ 75% improvement in the Eczema Area and Severity Index (41.0% and 27.0% vs 9.4%, respectively), ≥4-point improvement in itch (42.8% and 35.2% vs 18.2%, respectively), and ≥4-point improvement in Dermatology Life Quality Index (67.6% and 75.0% vs 49.5%, respectively) scores.

Study details: Findings are from a post hoc analysis of 1 phase 2b and 2 phase 3 (JADE Mono-1 and JADE Mono-2) trials including 548 patients with moderate-to-severe AD who were randomly assigned to receive abrocitinib (200 or 100 mg) or placebo and did not achieve IGA 0/1 response.

Disclosures: This study was funded by Pfizer Inc. Five authors declared being current or former employees and shareholders of Pfizer. The other authors reported ties with various sources, including Pfizer.

Source: Blauvelt A et al. Abrocitinib monotherapy in Investigator’s Global Assessment nonresponders: Improvement in signs and symptoms of atopic dermatitis and quality of life. J Dermatolog Treat. 2022 (Jul 6). Doi: 10.1080/09546634.2022.2059053

Key clinical point: Patients with moderate-to-severe atopic dermatitis (AD) who did not achieve Investigator's Global Assessment (IGA) 0/1 response with abrocitinib at week 12, still achieved clinically meaningful improvements in AD severity, itch, and quality of life.

Major finding: At week 12, a higher proportion of IGA nonresponders receiving 200 and 100 mg abrocitinib vs placebo achieved ≥ 75% improvement in the Eczema Area and Severity Index (41.0% and 27.0% vs 9.4%, respectively), ≥4-point improvement in itch (42.8% and 35.2% vs 18.2%, respectively), and ≥4-point improvement in Dermatology Life Quality Index (67.6% and 75.0% vs 49.5%, respectively) scores.

Study details: Findings are from a post hoc analysis of 1 phase 2b and 2 phase 3 (JADE Mono-1 and JADE Mono-2) trials including 548 patients with moderate-to-severe AD who were randomly assigned to receive abrocitinib (200 or 100 mg) or placebo and did not achieve IGA 0/1 response.

Disclosures: This study was funded by Pfizer Inc. Five authors declared being current or former employees and shareholders of Pfizer. The other authors reported ties with various sources, including Pfizer.

Source: Blauvelt A et al. Abrocitinib monotherapy in Investigator’s Global Assessment nonresponders: Improvement in signs and symptoms of atopic dermatitis and quality of life. J Dermatolog Treat. 2022 (Jul 6). Doi: 10.1080/09546634.2022.2059053

Key clinical point: Dupilumab led to clinically meaningful improvements in the severity of atopic dermatitis (AD) and was well tolerated in adolescents and children with moderate-to-severe AD.

Major finding: The mean improvement in the Eczema Area and Severity Index (EASI) was 59.6% at week 12-24 and 77.0% at week 36-48 (both P < .001), with all patients achieving ≥75% improvement in EASI score after a year or more of receiving dupilumab. Adverse events like conjunctivitis (5.6%) and joint pain (2.2%) were reported by 13.5% of patients.

Study details: Findings are from a retrospective observational study including 89 children and adolescents aged < 18 years with moderate-to-severe AD who initiated dupilumab treatment.

Disclosures: This study was funded by Pediatric Dermatology Research Alliance. Some authors declared serving as consultants or receiving research funds from several sources.

Source: Pagan AD et al. Dupilumab improves clinical scores in children and adolescents with moderate-to-severe atopic dermatitis: A real-world, single-center study. J Allergy Clin Immunol Pract. 2022 (Jun 23). Doi: 10.1016/j.jaip.2022.06.014

Key clinical point: Dupilumab led to clinically meaningful improvements in the severity of atopic dermatitis (AD) and was well tolerated in adolescents and children with moderate-to-severe AD.

Major finding: The mean improvement in the Eczema Area and Severity Index (EASI) was 59.6% at week 12-24 and 77.0% at week 36-48 (both P < .001), with all patients achieving ≥75% improvement in EASI score after a year or more of receiving dupilumab. Adverse events like conjunctivitis (5.6%) and joint pain (2.2%) were reported by 13.5% of patients.

Study details: Findings are from a retrospective observational study including 89 children and adolescents aged < 18 years with moderate-to-severe AD who initiated dupilumab treatment.

Disclosures: This study was funded by Pediatric Dermatology Research Alliance. Some authors declared serving as consultants or receiving research funds from several sources.

Source: Pagan AD et al. Dupilumab improves clinical scores in children and adolescents with moderate-to-severe atopic dermatitis: A real-world, single-center study. J Allergy Clin Immunol Pract. 2022 (Jun 23). Doi: 10.1016/j.jaip.2022.06.014

Key clinical point: Dupilumab led to clinically meaningful improvements in the severity of atopic dermatitis (AD) and was well tolerated in adolescents and children with moderate-to-severe AD.

Major finding: The mean improvement in the Eczema Area and Severity Index (EASI) was 59.6% at week 12-24 and 77.0% at week 36-48 (both P < .001), with all patients achieving ≥75% improvement in EASI score after a year or more of receiving dupilumab. Adverse events like conjunctivitis (5.6%) and joint pain (2.2%) were reported by 13.5% of patients.

Study details: Findings are from a retrospective observational study including 89 children and adolescents aged < 18 years with moderate-to-severe AD who initiated dupilumab treatment.

Disclosures: This study was funded by Pediatric Dermatology Research Alliance. Some authors declared serving as consultants or receiving research funds from several sources.

Source: Pagan AD et al. Dupilumab improves clinical scores in children and adolescents with moderate-to-severe atopic dermatitis: A real-world, single-center study. J Allergy Clin Immunol Pract. 2022 (Jun 23). Doi: 10.1016/j.jaip.2022.06.014

Key clinical point: Disease burden of atopic dermatitis (AD) is associated with multiple factors, with the strongest association being with disease severity, time spent managing AD symptoms, and comorbid depression.

Major finding: Disease burden was strongly associated with AD severity (moderate: odds ratio [OR] 4.13; 95% CI 2.94-5.79 or severe: OR 13.63; 95% CI 8.65-21.5 vs mild AD), time spent managing AD symptoms (11-20 hours/week: OR 2.67; 95% CI 1.77-4.03 or ≥21 hours/week: OR 5.34; 95% CI 3.22-8.85 vs 0-4 hours/week), and comorbid depression (OR 1.44; 95% CI 1.04-2.00).

Study details: Findings are from a survey study that analyzed the responses of 1065 adults with mostly moderate or severe AD.

Disclosures: This study was partly supported by National Eczema Association. The authors declared serving as fiscal agents or receiving grants, sponsorships, honoraria, or other compensation from several sources, including the National Eczema Association.

Source: Elsawi R et al. The multidimensional burden of atopic dermatitis among adults: Results from a large national survey. JAMA Dermatol. 2022 (Jun 29). Doi: 10.1001/jamadermatol.2022.1906

Key clinical point: Disease burden of atopic dermatitis (AD) is associated with multiple factors, with the strongest association being with disease severity, time spent managing AD symptoms, and comorbid depression.

Major finding: Disease burden was strongly associated with AD severity (moderate: odds ratio [OR] 4.13; 95% CI 2.94-5.79 or severe: OR 13.63; 95% CI 8.65-21.5 vs mild AD), time spent managing AD symptoms (11-20 hours/week: OR 2.67; 95% CI 1.77-4.03 or ≥21 hours/week: OR 5.34; 95% CI 3.22-8.85 vs 0-4 hours/week), and comorbid depression (OR 1.44; 95% CI 1.04-2.00).

Study details: Findings are from a survey study that analyzed the responses of 1065 adults with mostly moderate or severe AD.

Disclosures: This study was partly supported by National Eczema Association. The authors declared serving as fiscal agents or receiving grants, sponsorships, honoraria, or other compensation from several sources, including the National Eczema Association.

Source: Elsawi R et al. The multidimensional burden of atopic dermatitis among adults: Results from a large national survey. JAMA Dermatol. 2022 (Jun 29). Doi: 10.1001/jamadermatol.2022.1906

Key clinical point: Disease burden of atopic dermatitis (AD) is associated with multiple factors, with the strongest association being with disease severity, time spent managing AD symptoms, and comorbid depression.

Major finding: Disease burden was strongly associated with AD severity (moderate: odds ratio [OR] 4.13; 95% CI 2.94-5.79 or severe: OR 13.63; 95% CI 8.65-21.5 vs mild AD), time spent managing AD symptoms (11-20 hours/week: OR 2.67; 95% CI 1.77-4.03 or ≥21 hours/week: OR 5.34; 95% CI 3.22-8.85 vs 0-4 hours/week), and comorbid depression (OR 1.44; 95% CI 1.04-2.00).

Study details: Findings are from a survey study that analyzed the responses of 1065 adults with mostly moderate or severe AD.

Disclosures: This study was partly supported by National Eczema Association. The authors declared serving as fiscal agents or receiving grants, sponsorships, honoraria, or other compensation from several sources, including the National Eczema Association.

Source: Elsawi R et al. The multidimensional burden of atopic dermatitis among adults: Results from a large national survey. JAMA Dermatol. 2022 (Jun 29). Doi: 10.1001/jamadermatol.2022.1906

Key clinical point: Use of beta-adrenergic receptor blockers is associated with prolonged survival in patients with hepatocellular carcinoma (HCC).

Major finding: Beta-blocker use was associated with better overall survival (hazard ratio 0.69; P  =  .0031), with no significant heterogeneity across studies (I²  =  41%; P  =  .18).

Study details: The data come from a meta-analysis of 3 cohort studies involving 5148 patients with HCC that analyzed the association between the use of beta-blockers (including propranolol) and overall survival of the patients.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Chang H and Lee SH. Beta-adrenergic receptor blockers and hepatocellular carcinoma survival: A systemic review and meta-analysis. Clin Exp Med. 2022 (Jun 23). Doi: 10.1007/s10238-022-00842-z

Key clinical point: Use of beta-adrenergic receptor blockers is associated with prolonged survival in patients with hepatocellular carcinoma (HCC).

Major finding: Beta-blocker use was associated with better overall survival (hazard ratio 0.69; P  =  .0031), with no significant heterogeneity across studies (I²  =  41%; P  =  .18).

Study details: The data come from a meta-analysis of 3 cohort studies involving 5148 patients with HCC that analyzed the association between the use of beta-blockers (including propranolol) and overall survival of the patients.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Chang H and Lee SH. Beta-adrenergic receptor blockers and hepatocellular carcinoma survival: A systemic review and meta-analysis. Clin Exp Med. 2022 (Jun 23). Doi: 10.1007/s10238-022-00842-z

Key clinical point: Use of beta-adrenergic receptor blockers is associated with prolonged survival in patients with hepatocellular carcinoma (HCC).

Major finding: Beta-blocker use was associated with better overall survival (hazard ratio 0.69; P  =  .0031), with no significant heterogeneity across studies (I²  =  41%; P  =  .18).

Study details: The data come from a meta-analysis of 3 cohort studies involving 5148 patients with HCC that analyzed the association between the use of beta-blockers (including propranolol) and overall survival of the patients.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Chang H and Lee SH. Beta-adrenergic receptor blockers and hepatocellular carcinoma survival: A systemic review and meta-analysis. Clin Exp Med. 2022 (Jun 23). Doi: 10.1007/s10238-022-00842-z

Key clinical point: First-line lenvatinib plus idarubicin-loaded drug-eluting bead transarterial chemoembolization (IDADEB-TACE) is safe and offers a better safety profile than lenvatinib alone in patients with advanced hepatocellular carcinoma (HCC).

Major finding: Patients receiving lenvatinib plus IDADEB-TACE vs lenvatinib alone had a significantly higher objective response rate (57.7% vs 25.7%; P < .001), longer median overall survival (15.7 vs 11.3 months; hazard ratio 0.50; P < .001), and comparable toxicity profile, with most adverse events being mild and manageable.

Study details: Findings are from a multicenter, retrospective cohort study that propensity-score matched patients with advanced HCC who received lenvatinib plus IDADEB-TACE (n = 78) with those who received lenvatinib alone (n = 78).

Disclosures: This study was sponsored by the National Natural Science Foundation of China, among others. The authors reported no conflicts of interest.

Source: Fan W et al. Idarubicin-loaded DEB-TACE plus lenvatinib versus lenvatinib for patients with advanced hepatocellular carcinoma: A propensity score-matching analysis. Cancer Med. 2022 (Jun 13). Doi: 10.1002/cam4.4937

Key clinical point: First-line lenvatinib plus idarubicin-loaded drug-eluting bead transarterial chemoembolization (IDADEB-TACE) is safe and offers a better safety profile than lenvatinib alone in patients with advanced hepatocellular carcinoma (HCC).

Major finding: Patients receiving lenvatinib plus IDADEB-TACE vs lenvatinib alone had a significantly higher objective response rate (57.7% vs 25.7%; P < .001), longer median overall survival (15.7 vs 11.3 months; hazard ratio 0.50; P < .001), and comparable toxicity profile, with most adverse events being mild and manageable.

Study details: Findings are from a multicenter, retrospective cohort study that propensity-score matched patients with advanced HCC who received lenvatinib plus IDADEB-TACE (n = 78) with those who received lenvatinib alone (n = 78).

Disclosures: This study was sponsored by the National Natural Science Foundation of China, among others. The authors reported no conflicts of interest.

Source: Fan W et al. Idarubicin-loaded DEB-TACE plus lenvatinib versus lenvatinib for patients with advanced hepatocellular carcinoma: A propensity score-matching analysis. Cancer Med. 2022 (Jun 13). Doi: 10.1002/cam4.4937

Key clinical point: First-line lenvatinib plus idarubicin-loaded drug-eluting bead transarterial chemoembolization (IDADEB-TACE) is safe and offers a better safety profile than lenvatinib alone in patients with advanced hepatocellular carcinoma (HCC).

Major finding: Patients receiving lenvatinib plus IDADEB-TACE vs lenvatinib alone had a significantly higher objective response rate (57.7% vs 25.7%; P < .001), longer median overall survival (15.7 vs 11.3 months; hazard ratio 0.50; P < .001), and comparable toxicity profile, with most adverse events being mild and manageable.

Study details: Findings are from a multicenter, retrospective cohort study that propensity-score matched patients with advanced HCC who received lenvatinib plus IDADEB-TACE (n = 78) with those who received lenvatinib alone (n = 78).

Disclosures: This study was sponsored by the National Natural Science Foundation of China, among others. The authors reported no conflicts of interest.

Source: Fan W et al. Idarubicin-loaded DEB-TACE plus lenvatinib versus lenvatinib for patients with advanced hepatocellular carcinoma: A propensity score-matching analysis. Cancer Med. 2022 (Jun 13). Doi: 10.1002/cam4.4937

Key clinical point: Direct-acting antiviral (DAA) therapy prevents recurrence and improves overall survival (OS) in patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC), especially in those with a sustained virologic response (SVR).

Major finding: Patients receiving DAA vs no therapy had a significantly reduced recurrence (adjusted hazard ratio [aHR] 0.55; P < .001) and improved OS (aHR 0.36; P  =  .017). After DAA therapy, patients with SVR vs nonresponders had significantly lower recurrence rates (hazard ratio [HR] 0.37; P  =  .017) and mortality (HR 0.17; P  =  .001).

Study details: This was a meta-analysis of 23 cohort studies that evaluated the effects of DAA therapy, interferon therapy, or no intervention on recurrence or OS in patients with HCV-related HCC.

Disclosures: This study was sponsored by the Taishan Scholars Program for Young Expert of Shandong Province, China, among others. The authors declared no conflicts of interest.

Source: Liu H et al. Clinical benefits of direct-acting antivirals therapy in hepatitis C virus patients with hepatocellular carcinoma: A systematic review and meta-analysis. J Gastroenterol Hepatol. 2022 (Jun 20). Doi: 10.1111/jgh.15915

Key clinical point: Direct-acting antiviral (DAA) therapy prevents recurrence and improves overall survival (OS) in patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC), especially in those with a sustained virologic response (SVR).

Major finding: Patients receiving DAA vs no therapy had a significantly reduced recurrence (adjusted hazard ratio [aHR] 0.55; P < .001) and improved OS (aHR 0.36; P  =  .017). After DAA therapy, patients with SVR vs nonresponders had significantly lower recurrence rates (hazard ratio [HR] 0.37; P  =  .017) and mortality (HR 0.17; P  =  .001).

Study details: This was a meta-analysis of 23 cohort studies that evaluated the effects of DAA therapy, interferon therapy, or no intervention on recurrence or OS in patients with HCV-related HCC.

Disclosures: This study was sponsored by the Taishan Scholars Program for Young Expert of Shandong Province, China, among others. The authors declared no conflicts of interest.

Source: Liu H et al. Clinical benefits of direct-acting antivirals therapy in hepatitis C virus patients with hepatocellular carcinoma: A systematic review and meta-analysis. J Gastroenterol Hepatol. 2022 (Jun 20). Doi: 10.1111/jgh.15915

Key clinical point: Direct-acting antiviral (DAA) therapy prevents recurrence and improves overall survival (OS) in patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC), especially in those with a sustained virologic response (SVR).

Major finding: Patients receiving DAA vs no therapy had a significantly reduced recurrence (adjusted hazard ratio [aHR] 0.55; P < .001) and improved OS (aHR 0.36; P  =  .017). After DAA therapy, patients with SVR vs nonresponders had significantly lower recurrence rates (hazard ratio [HR] 0.37; P  =  .017) and mortality (HR 0.17; P  =  .001).

Study details: This was a meta-analysis of 23 cohort studies that evaluated the effects of DAA therapy, interferon therapy, or no intervention on recurrence or OS in patients with HCV-related HCC.

Disclosures: This study was sponsored by the Taishan Scholars Program for Young Expert of Shandong Province, China, among others. The authors declared no conflicts of interest.

Source: Liu H et al. Clinical benefits of direct-acting antivirals therapy in hepatitis C virus patients with hepatocellular carcinoma: A systematic review and meta-analysis. J Gastroenterol Hepatol. 2022 (Jun 20). Doi: 10.1111/jgh.15915

Key clinical point: Statin use is associated with a lower risk for hepatocellular carcinoma (HCC) incidence in dialysis patients with chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection.

Major finding: Statin users vs nonusers had a 41% reduced risk for HCC (subdistribution hazard ratio 0.59; P  =  .001) and a lower weighted HCC incidence rate (incidence rate difference −3.7; P < .001), with the incidence rate ratio being 0.56 (P < .001).

Study details: This retrospective observational study included 6165 patients aged ≥ 19 and < 85 years with HBV or HCV infection who were on maintenance dialysis and received ≥28 cumulative defined daily doses of statins (users; n = 2655) or did not receive statins (nonusers; n = 3510) in the first 3 months after dialysis commencement.

Disclosures: No financial support was reported. The authors declared no conflicts of interest.

Source: Kim HW et al. Association of statin treatment with hepatocellular carcinoma risk in end-stage kidney disease patients with chronic viral hepatitis. Sci Rep. 2022;12:10807 (Jun 25. Doi: 10.1038/s41598-022-14713-w

Key clinical point: Statin use is associated with a lower risk for hepatocellular carcinoma (HCC) incidence in dialysis patients with chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection.

Major finding: Statin users vs nonusers had a 41% reduced risk for HCC (subdistribution hazard ratio 0.59; P  =  .001) and a lower weighted HCC incidence rate (incidence rate difference −3.7; P < .001), with the incidence rate ratio being 0.56 (P < .001).

Study details: This retrospective observational study included 6165 patients aged ≥ 19 and < 85 years with HBV or HCV infection who were on maintenance dialysis and received ≥28 cumulative defined daily doses of statins (users; n = 2655) or did not receive statins (nonusers; n = 3510) in the first 3 months after dialysis commencement.

Disclosures: No financial support was reported. The authors declared no conflicts of interest.

Source: Kim HW et al. Association of statin treatment with hepatocellular carcinoma risk in end-stage kidney disease patients with chronic viral hepatitis. Sci Rep. 2022;12:10807 (Jun 25. Doi: 10.1038/s41598-022-14713-w

Key clinical point: Statin use is associated with a lower risk for hepatocellular carcinoma (HCC) incidence in dialysis patients with chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection.

Major finding: Statin users vs nonusers had a 41% reduced risk for HCC (subdistribution hazard ratio 0.59; P  =  .001) and a lower weighted HCC incidence rate (incidence rate difference −3.7; P < .001), with the incidence rate ratio being 0.56 (P < .001).

Study details: This retrospective observational study included 6165 patients aged ≥ 19 and < 85 years with HBV or HCV infection who were on maintenance dialysis and received ≥28 cumulative defined daily doses of statins (users; n = 2655) or did not receive statins (nonusers; n = 3510) in the first 3 months after dialysis commencement.

Disclosures: No financial support was reported. The authors declared no conflicts of interest.

Source: Kim HW et al. Association of statin treatment with hepatocellular carcinoma risk in end-stage kidney disease patients with chronic viral hepatitis. Sci Rep. 2022;12:10807 (Jun 25. Doi: 10.1038/s41598-022-14713-w

Key clinical point: Lenvatinib-based combination therapies are associated with a significantly longer progression-free survival (PFS) and better objective response (OR) than lenvatinib monotherapy in patients with hepatocellular carcinoma (HCC).

Major finding: Lenvatinib combination therapy vs monotherapy was associated with a significantly longer PFS (Response Evaluation Criteria in Solid Tumours [RECIST] v1.1: 7.77 vs 4.43 months; P  =  .045; modified RECIST [mRECIST]: 6.97 vs 5.27 months; P  =  .067) and a higher OR rate (RECIST v1.1: 37% vs 5%; P < .001; mRECIST: 53% vs 11%; P < .001) but no significant overall survival benefit (P  =  .71).

Study details: Findings are from a retrospective study that included 215 patients with HCC who received lenvatinib-based therapies.

Disclosures: This study was funded by the National Key R&D Program of China and National Natural Science Foundation of China. The authors declared no conflicts of interest.

Source: Chen J et al. The combination treatment strategy of lenvatinib for hepatocellular carcinoma: a real-world study. J Cancer Res Clin Oncol. 2022 (Jun 25). Doi: 10.1007/s00432-022-04082-2

Key clinical point: Lenvatinib-based combination therapies are associated with a significantly longer progression-free survival (PFS) and better objective response (OR) than lenvatinib monotherapy in patients with hepatocellular carcinoma (HCC).

Major finding: Lenvatinib combination therapy vs monotherapy was associated with a significantly longer PFS (Response Evaluation Criteria in Solid Tumours [RECIST] v1.1: 7.77 vs 4.43 months; P  =  .045; modified RECIST [mRECIST]: 6.97 vs 5.27 months; P  =  .067) and a higher OR rate (RECIST v1.1: 37% vs 5%; P < .001; mRECIST: 53% vs 11%; P < .001) but no significant overall survival benefit (P  =  .71).

Study details: Findings are from a retrospective study that included 215 patients with HCC who received lenvatinib-based therapies.

Disclosures: This study was funded by the National Key R&D Program of China and National Natural Science Foundation of China. The authors declared no conflicts of interest.

Source: Chen J et al. The combination treatment strategy of lenvatinib for hepatocellular carcinoma: a real-world study. J Cancer Res Clin Oncol. 2022 (Jun 25). Doi: 10.1007/s00432-022-04082-2

Key clinical point: Lenvatinib-based combination therapies are associated with a significantly longer progression-free survival (PFS) and better objective response (OR) than lenvatinib monotherapy in patients with hepatocellular carcinoma (HCC).

Major finding: Lenvatinib combination therapy vs monotherapy was associated with a significantly longer PFS (Response Evaluation Criteria in Solid Tumours [RECIST] v1.1: 7.77 vs 4.43 months; P  =  .045; modified RECIST [mRECIST]: 6.97 vs 5.27 months; P  =  .067) and a higher OR rate (RECIST v1.1: 37% vs 5%; P < .001; mRECIST: 53% vs 11%; P < .001) but no significant overall survival benefit (P  =  .71).

Study details: Findings are from a retrospective study that included 215 patients with HCC who received lenvatinib-based therapies.

Disclosures: This study was funded by the National Key R&D Program of China and National Natural Science Foundation of China. The authors declared no conflicts of interest.

Source: Chen J et al. The combination treatment strategy of lenvatinib for hepatocellular carcinoma: a real-world study. J Cancer Res Clin Oncol. 2022 (Jun 25). Doi: 10.1007/s00432-022-04082-2

Key clinical point: Lenvatinib-based combination therapies are associated with a significantly longer progression-free survival (PFS) and better objective response (OR) than lenvatinib monotherapy in patients with hepatocellular carcinoma (HCC).

Major finding: Lenvatinib combination therapy vs monotherapy was associated with a significantly longer PFS (Response Evaluation Criteria in Solid Tumours [RECIST] v1.1: 7.77 vs 4.43 months; P  =  .045; modified RECIST [mRECIST]: 6.97 vs 5.27 months; P  =  .067) and a higher OR rate (RECIST v1.1: 37% vs 5%; P < .001; mRECIST: 53% vs 11%; P < .001) but no significant overall survival benefit (P  =  .71).

Study details: Findings are from a retrospective study that included 215 patients with HCC who received lenvatinib-based therapies.

Disclosures: This study was funded by the National Key R&D Program of China and National Natural Science Foundation of China. The authors declared no conflicts of interest.

Source: Chen J et al. The combination treatment strategy of lenvatinib for hepatocellular carcinoma: a real-world study. J Cancer Res Clin Oncol. 2022 (Jun 25). Doi: 10.1007/s00432-022-04082-2

Key clinical point: Lenvatinib-based combination therapies are associated with a significantly longer progression-free survival (PFS) and better objective response (OR) than lenvatinib monotherapy in patients with hepatocellular carcinoma (HCC).

Major finding: Lenvatinib combination therapy vs monotherapy was associated with a significantly longer PFS (Response Evaluation Criteria in Solid Tumours [RECIST] v1.1: 7.77 vs 4.43 months; P  =  .045; modified RECIST [mRECIST]: 6.97 vs 5.27 months; P  =  .067) and a higher OR rate (RECIST v1.1: 37% vs 5%; P < .001; mRECIST: 53% vs 11%; P < .001) but no significant overall survival benefit (P  =  .71).

Study details: Findings are from a retrospective study that included 215 patients with HCC who received lenvatinib-based therapies.

Disclosures: This study was funded by the National Key R&D Program of China and National Natural Science Foundation of China. The authors declared no conflicts of interest.

Source: Chen J et al. The combination treatment strategy of lenvatinib for hepatocellular carcinoma: a real-world study. J Cancer Res Clin Oncol. 2022 (Jun 25). Doi: 10.1007/s00432-022-04082-2

Key clinical point: Lenvatinib-based combination therapies are associated with a significantly longer progression-free survival (PFS) and better objective response (OR) than lenvatinib monotherapy in patients with hepatocellular carcinoma (HCC).

Major finding: Lenvatinib combination therapy vs monotherapy was associated with a significantly longer PFS (Response Evaluation Criteria in Solid Tumours [RECIST] v1.1: 7.77 vs 4.43 months; P  =  .045; modified RECIST [mRECIST]: 6.97 vs 5.27 months; P  =  .067) and a higher OR rate (RECIST v1.1: 37% vs 5%; P < .001; mRECIST: 53% vs 11%; P < .001) but no significant overall survival benefit (P  =  .71).

Study details: Findings are from a retrospective study that included 215 patients with HCC who received lenvatinib-based therapies.

Disclosures: This study was funded by the National Key R&D Program of China and National Natural Science Foundation of China. The authors declared no conflicts of interest.

Source: Chen J et al. The combination treatment strategy of lenvatinib for hepatocellular carcinoma: a real-world study. J Cancer Res Clin Oncol. 2022 (Jun 25). Doi: 10.1007/s00432-022-04082-2